Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Study to Evaluate the Feasibility and Efficacy of Sequential Abemaciclib and Gemcitabine Treatment in Patients With Retinoblastoma (Rb)+ Sarcomas

Next Previous
Trial Profile

Phase I/II Study to Evaluate the Feasibility and Efficacy of Sequential Abemaciclib and Gemcitabine Treatment in Patients With Retinoblastoma (Rb)+ Sarcomas

Status: Suspended
Phase of Trial: Phase I/II

Latest Information Update: 22 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary) ; F-18 fluorothymidine (Primary) ; Docetaxel; Gemcitabine
  • Indications Leiomyosarcoma; Liposarcoma; Soft tissue sarcoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 17 Apr 2025 Status changed from recruiting to suspended.
  • 12 Mar 2025 Status changed from suspended to recruiting.
  • 14 Feb 2025 Status changed from recruiting to suspended, as per CS0174893, there were zero accruals.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top